先前的研究指出，大約有50-70%的黑色素瘤包含BRaf基因的突變，其中80%是V600E的取代突變，這個突變持續性地誘導MAPK/ERK訊息傳導路徑的活化也造成癌症的惡性表現型。很多訊息傳導路徑被發現會被微型RNA調控；然而，微型RNA、黑色素瘤與MAPK路徑之間的關聯性尚不明確。從先前微陣列晶片實驗和GEO資料庫篩選出與MAPK相關的微型RNA。為了更深入的研究，未來將會實施動物實驗。闡明微型RNA在黑色素瘤中的角色可能可以提供其作為癌症生物標記或微型RNA的標靶治療。;It has been reported that approximately 50-70% of melanoma samples contain BRaf mutations, 80% of which is V600E. The mutation constitutively induces high activity in MAPK/ERK signaling pathway and causes malignant phenotypes of cancers. MAPK/ERK signaling may be modulated by microRNA (miRNA); however, correlations between miRNA, melanoma and MAPK/ERK pathway are still unclear. We screen out MAPK-related miRNA from the prior microarray results and GEO data analysis. For further investigation, experiments should be performed in vivo in the future. Elucidating the role of miRNAs in melanoma may provide as biomarkers or a miRNA-targeting therapy for cancers.